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when the generic drug is in the form of a different salt to the originator as well as different indications initially, as seen with generic clopidogrel [24] . Two recent comprehensive reviews illustrate this by comparing the outcomes between generic and originator drugs for the treatment of two widely different diseases [25, 26] . The fi rst review considered treatments for epilepsy and found no evidence of association between loss of seizure control and treatment with at least three types of antiepileptic drugs, one of which was phenytoin [25] . Similarly, the second review, which focused on the treatment of cardiovascular disease, did not demonstrate superiority in outcomes for originators compared to generic drugs [26] . This included drugs with a narrow therapeutic index such as propafenone and warfarin [26] . Therefore, generic medicines can help conserve valuable resources without compromising the quality of care [1, 3-6, 8, 13-17, 20, 27] .
Many different measures and initiatives have increased prescribing effi ciency in Europe, and are summarised in a previous edition of the GaBI Journal [1, 27] .
These resulted in generic medicines in Europe comprising 50% of the volume of dispensed drugs but only 18% of the expenditure on drugs in 2006 [19, 28] , leading to estimated annual savings of Euros 25 billion per year among the 27 nations in the EU [28] . Expenditure on generics in Europe was 21% in 2007, with the EU accounting for 30% of worldwide sales of generics in 2007 [28] . The extent of the savings is helped by estimated price reductions of between 30% to 90% for generics versus originator prices just prior to patent loss, with typically between 10 to 30 manufacturers competing to supply the different generic products in each market [20, 27, 28] .
In the US, the prescribing of generics is also gaining ground. For example, published studies have consistently shown that among managed care organisations (MCOs) co-payment tier levels three and four are associated with decreased use of prescription drugs [29] . This even applies to patients with chronic conditions with higher morbidity and mortality such as diabetes, hypertension and hypercholesterolemia [29] . On the other hand, there is improved adherence to drug therapy if patients are prescribed generic drugs with typically the lowest co-payment levels-Tier One [29] . These fi ndings [29] are further substantiated with recent research reporting that 'dispense as written' requests from physicians in the US, aimed at reducing generics substitution leading to higher co-payments, were again associated with decreased rates of prescription fi lling [30] .
However, there are concerns with the effectiveness and tolerability of generics compared with originator drugs [3, 7, 24, [31] [32] [33] [34] [35] [36] [37] , with some originator companies questioning the quality of generics as part of their marketing strategies to reduce the erosion of sales which follow patent loss [38] . Whilst these concerns typically only apply to a minority of situations [34, 36, 39] , as demonstrated for instance by 'dispense as written' prescriptions only accounting for 2.7% of prescriptions written by physicians in the US [30] , failure by health authorities, physicians and pharmacists to adequately address these concerns will mean reduced savings in reality [3-5, 17, 40] . Potential concerns regarding the effectiveness and tolerability of generics, and associated reduced savings from lower utilisation rates, have stimulated health authorities and health insurance agencies to instigate new initiatives to address these concerns, see Tables 1, 2 and 3. There are also concerns among payers at the considerable variation in the price of generics. These can vary up to 36 fold among European countries and India, and greater than 50 fold among developing countries, depending on the molecule [2, 4, 20] . The price differences are independent of the population size of the country or levels of income [10, 41] , and are leading some countries to continually review their generics pricing strategies so as to enhance resource savings [3, 4, 7, [9] [10] [11] [12] [13] [14] [15] [16] . There is also wide variation across Europe in the utilisation of generics versus patent-protected products in the same class or related class [4, 5, 8, 11] . Reducing this variation will likewise enable payers to conserve additional resources as generic drugs become increasingly available [4, 8, 12, 13] .
In the future it is likely there will be further expansion in the manufacture and availability of generics, given the likely size of the market. For example, global sales of pharmaceuticals were estimated at US$820 billion in 2009 [1] . However between 2011 and 2016, products with current sales of US$255 billion per year are likely to lose their patents [42] . This is in addition to high volume products that have already lost their patents in the past decade including various proton pump inhibitors (PPIs), statins, selective serotonin re-uptake inhibitors (SSRIs) and angiotensin converting enzyme inhibitors (ACEIs), helping to conserve resources [1, 4, 5-9, 11, 16, 18, 43] .
As a result of the burgeoning availability of generics, and the concerns outlined above, payers need to continue to learn from each other regarding potential additional measures to further conserve costs as resource pressures grow.
Study objectives
The principal objective of this paper is to produce guidance on potential ways to conserve resources around the use of generics especially to payers of health care. To this end, this paper fi rstly reviews measures that have been successfully introduced in different countries; secondly, potential pitfalls that could arise. The latter needs to be heeded to optimise potential savings from the increasing availability of generics.
Methods
This is a narrative review of case histories. There is no systematic review of initiatives to enhance the utilisation of generics at low prices since these reviews have already been undertaken and published elsewhere including those by the co-authors [4, 5, 8, 11, 18, 27] .
The case histories have been selected by co-authors to meet the objectives of the paper rather than document a specifi c number of case histories from each continent. They have been divided into those predominantly concerned with supply-side measures, those predominantly discussing demand-side measures, those combining both approaches, and fi nally those where payers have not always been able to fully realise potential savings. 
Germany [4, 8, 46-48]
A) Measures to enhance the prescribing and dispensing of generics in Germany during the past decade include:
• Abolishing patient co-payments if the reimbursed price of the dispensed generics is at least 30% below the current reference price • Potentially reducing or abolishing co-payments if physicians prescribe drugs that Sickness Funds have successfully negotiated contracts with pharmaceutical companies, which include both patent-protected products and branded generics • Enhancing the prescribing of generics through fi nancial penalties for physicians not reaching agreed target levels for prescribing generics including biosimilars versus originators, alongside reduced prescribing of premium priced patented drugs and expensive me-too drugs in a class B) Outcomes The rebates, included those for patented drugs, amounted to estimated savings of Euros 1.3 billion for the Statutory Health Insurance Funds in Germany in 2010.
However, despite these measures the reimbursed prices of generics can be appreciably higher in Germany than the UK, with the UK introducing measures to enhance transparency in the pricing of generics, see Table 1A . The methodology outlined in Table 1A estimated potential savings of over Euros 1.4 billion in 2010 for the 50 leading generic products, and Euros 5.0 billion for the total generics market, if prices in Germany were aligned to those in the UK.
Sweden [7, 49, 50]
A) Current measures Compulsory generics substitution was introduced in Sweden in 2002 to conserve resources. The implementation, which helped reduce reimbursed prices of high volume generics to between 4 and 13% of originator prices before they lost their patents, was assisted by the monopoly on community pharmacists, which all belonged to Apoteket AB. Pharmacists were until 2009 obligated to dispense the cheapest multiple source product available at the local pharmacy.
There were however occasions when prices of some generics rose from one month to the next. In addition, there is currently competition among community pharmacists in Sweden.
As a result, the government commissioned TLV (Swedish Reimbursement Agency) in the late 2000's to establish new regulations for the de-monopolised pharmacy market incorporating increased service levels and accessibility of pharmacies, without increasing the costs of medicines. Following this, all pharmacies since 2009 are obligated to offer patients the cheapest molecule on the market when there are substitutable generic medicines available. In return, pharmacies received Euros 1/ package extra in their retail margin when they dispense drugs subject to generics competition.
(Continued) REVIEW ARTICLE In addition under the new agreement, there are regular monthly auctions of potential prices for each generic drug. Quarterly auctions were considered but rejected due to concerns with breaching the European Transparency Directive. Under this new system, the manufacturer with the lowest price wins the auction. However, the chosen manufacturer for a respective generic drug must be able to supply the whole market for the entire period. Having the current cheapest product gives the pertinent manufacturer exclusivity to the market. This equates to approximately 70% of the total sales during the period and almost 80% if crossed prescriptions, i.e. medicines that are not interchangeable due to medical reasons, are included.
To overcome potential supply issues, pharmacies are allowed to dispense an additional two further branded generics of the molecule when the cheapest medicine is out-of-stock at the wholesaler. They also have a 15-day washout period to de-stock the previous month's cheapest generic drug if pertinent. Pharmacies cannot choose freely between the three products. However, they can only offer patients the next cheapest generic drug in exceptional circumstance such as when there are delivery problems.
B) Next steps and future refi nements Since 2009, TLV has also been charged with monitoring and supervising pertinent areas of the pharmacy market, i.e. evaluating if pharmacies have been following the regulations such as those relating to substitution and how this has impacted on the supply of generics, prices of generics and reduced fl uctuations in practice. This will be reported shortly.
TLV is also currently reviewing their remuneration to pharmacists due to concerns with the existing level of remuneration to fully compensate pharmacists for spending time if needed with patients each month explaining that the different branded generic drug is in fact the same molecule as their prescription.
Where possible, each case history documents the measures undertaken as well as the outcomes. No set format has been used to document the measures undertaken as their nature varies by country depending on the current situation and circumstances. In addition, in some countries there is an iterative approach to successive reforms such as Australia.
Whilst this may represent a limitation to the study design, we have counter-balanced this by including as co-authors those directly involved in implementing the reforms. Consequently, we believe this approach provides the most comprehensive and accurate insight into the situation in the respective countries. This approach has worked well in previous publications [1, [3] [4] [5] [6] [7] [8] [9] [10] [11] [14] [15] [16] [17] [18] , and is seen as preferable to obtaining information solely through interviews.
Results
As discussed under methodology, selected case histories have been divided into those predominantly concerned with supplyside measures, see Table 1 ; those documenting predominantly demand-side measures, see Table 2 ; as well as those combining both approaches, see Table 3 .
However, there have been situations where health authorities and health insurance agencies have failed to realise the full resource benefi ts from the availability of generics, although this is changing through the instigation of additional measures, see Table 4 .
Discussion
As can be seen in Tables 1 to 4 , payers across Europe, Middle East (United Arab Emirates), Australia and the US have introduced a range of measures to try and enhance the utilisation of generics as well as obtain lower prices, in order to try and maximise the opportunity that generics provide for conserving valuable resources.
Successful supply-side measures include aggressive pricing of the generics as seen in Lithuania, see Table 3 , as well as increased transparency in the pricing of generics to further lower generics prices. The latter is seen in the UK, see Table 3 .
As discussed, the situation in Lithuania, see Table 3 , demonstrates that it is possible for European countries with small populations to obtain low prices for their drugs despite the rhetoric [10, 60] . As a result, this helps to continue providing access to drugs even though drug budgets are being cut. This is also seen in Croatia with their extensive range of principally supply-side measures, see Table 1 , regarding the pricing of generic and other drugs for the molecule (ATC Level 5) as well as the class (ATC Level 3 and 4). The various measures in Croatia helped engineer suffi cient budgetary space to reduce the budget arrears to pharmacies as well as increase the availability to new drugs [13] .
The monthly auction for generics prices in Sweden is a novel approach, which can potentially be transferable across countries. However, more analysis needs to be undertaken before this can occur, see Table 1 . The specifi c contracting between pharmaceutical companies and individual sickness funds in Germany is also an interesting development, see Table 1 . However, potentially greater savings could occur through more aggressive pricing policies for generics, see Table 1A . These though may take considerable time to implement; consequently, current practices in Germany could be a good compromise.
Demand-side measures to address physician and patient concerns have been successfully introduced in France leading to appreciable savings when combined with prescriptive pricing policies for generics, see Table 2 . As a result, this provides direction to other countries faced with similar concerns. Similarly, the recent initiatives among MCOs in the US to enhance the use of generics within a class to improve both the quality and effi ciency of care, especially where the outcome and safety of new drugs has not been established, also provides direction to other countries. This mirrors the situation in for instance Stockholm in Sweden with its 'Wise List' of approximately 200 recommended drugs in ambulatory care [64] . These are predominantly well-established generic drugs, with a recent ecological study showing no difference in surrogate measures in patients with diabetes, hypertension of hypercholesterolaemia between patients prescribed well-established generic drugs compared with those prescribed patent-protected drugs; however considerable differences in costs [65] .
The combination of multiple supply-and demand-side measures has appreciably improved prescribing effi ciency for high volume drugs in Scotland, also providing direction to other countries, see Table 3 . An important message, based on the experiences of NHS Bury, is for health authorities and health insurance agencies to pro-actively monitor products shortly losing their patent and plan for this through switching and other activities where this is possible, see Table 3 . As a result, fully capitalise on generics as soon as they become available.
Additional measures to enhance the prescribing of generics include compulsory or voluntary INN prescribing. This has the potential to reduce patient confusion where patients are prescribed a different brand of generics at each prescription [9, 66] as well as the potential for duplication of REVIEW ARTICLE • Guaranteed the same absolute margin for both generic and originator medicines. They also receive a maximum discount of 17% of the ex-factory price for generic products • Since 2006, substitution targets are determined annually and published as an amendment to the national agreement between the pharmacists and the Health Insurance Funds. The last amendment was published in April 2010 and, in addition to a list of molecules with specifi c targets, there was also a list of targets for each regional territory in France (approximately 100) to further enhance generics substitution iii) Patients:
• 
USA Managed Care Organizations (MCOs) -Blue Cross Blue Shield [9, 52-54]
A) Current situation The prescribing of generics is a major priority area among MCOs in the US from both a cost saving as well as a clinical perspective.
Some manufacturers launch 'branded generics' at similar prices to originators. This is leading MCOs in recent years to closely monitor the situation and, in most cases, block these 'branded generics' from formulary inclusion. This is because the inclusion of branded generics may affect the overall level of rebates offered by pharmaceutical companies for reaching combined sales targets for all their originator products included in the formulary.
In addition, there is increasing awareness that the current situation of allowing six months exclusivity for the fi rst generic drug on the market for a particular molecule also does not result in appreciable savings during this period. Consequently, again most MCO's now block the formulary inclusion of these generics especially if they reduce the level of rebates offered by the originator pharmaceutical company for the range of products on the formulary. Another option is to place these fi rst generics on the third tier (typically MCOs have three to four Tiers on their formulary with successively higher co-payment from Tier One to Tier Four -mentioned earlier), which is associated with an appreciable higher patient co-payment. In addition, in some cases putting the originator in the generics tier (fi rst tier for co-pay), and passing savings from moving the product from the second tier (higher co-payment) to the fi rst tier directly onto members. The tier situation for both the originator and the generics is revised once multiple generics become available at appreciably lower acquisition prices than the fi rst generic drug.
Alongside this, in the past generics utilisation has generally been promoted as 'cost saving', which has been perceived negatively by some members. This is resulting in MCOs now promoting generics under the 'clinical safety umbrella' alongside cost savings. The clinical evaluation conducted by many MCO Pharmacy and Therapeutic Committees now supports and broadcasts the utilisation of generics not only on the basis of cost savings once multiple sources are available but also on the basis of the clinical experience for a molecule. This arises from the long patent life, which provides considerable clinical and safety data including outcomes over time. These data are typically lacking from newly launched non-generic products.
(Continued) The economy is also a big driver of generics use, especially where employer groups are facing the challenges of increased costs due to the infl ux of premium priced me-too brands. Consequently, employers are now increasingly requesting formulary designs that will be cost-effective as well as clinically optimum, i.e. without compromising care. As a result, the introduction of Advantage formularies -where therapeutic classes that have generics available require a failure of a generic drug before a patentprotected product is prescribed -are becoming very popular, and almost every MCO is now offering this option.
The introduction of US$4 generics programmes (Tier One) is also increasing the utilisation of generics, as well as increasing the awareness of generics among the general population. Many MCOs are also now actively promoting cross therapeutic opportunities for generics substitution where the effectiveness and safety of a particular generic product is similar to a patent-protected product in the same or related class, mirroring the situation in, for instance, Norway and the UK promoting substitution of patent-protected atorvastatin with generic simvastatin. This rationale for promoting this approach is enhanced when comparing the known effi cacy and safety of generics versus newer patent-protected products with limited outcome and safety data. Consequently, it is likely that the steady increase in the percentage of prescriptions dispensed as generics will continue to rise beyond 78% of all prescriptions seen in 2010.
B) Supreme Court Ruling and subsequent activities
In the 2009 case Wyeth vs Levine, the Supreme Court in the US ruled that manufacturers of brand-name drugs could be sued under state law for failing to adequately warn patients of any new patient safety risks discovered after the drug was approved. The Supreme Court accepted though the FDA's beliefs of the situation regarding generics, and held that State Courts were preempted from making any fi nding of liability based on a generic drug manufacturer's failure to change its label. However, in the future, FDA believes that generics manufacturers have a duty to propose stronger warning labels if needed as more clinical data becomes available. This was a 5-4 decision, and a reversal of the previous rulings.
Alongside this, FDA is increasingly taking strict actions where they believe the safety of a generic drug is being breached, e.g. generic voltaren eye drops were withdrawn from the market when there were safety concerns.
As a result of this ruling, although still under discussion, it is likely the package insert of generics will be more regularly updated with safety information. • The fi rst generics of a molecule to receive marketing authorisation must be priced at least 30% below the originator to be reimbursed • The second and third generics must be priced at least 10% below the fi rst generics to be reimbursed • Market forces after this to lower the prices of the fourth and subsequent generics with patients having to cover the additional costs themselves for a more expensive drug than the current referenced priced molecule (typically the lowest priced molecule) • When more than three products with the same INN name are eligible to be reimbursed, the originator must not be priced higher than 50% above the average price of the two cheapest generics for continued reimbursement • INN prescribing is mandatory unless a biological drug is prescribed or physicians receive prior approval from the Hospital 
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UK-Primary Care Trusts
A) Measures • As part of their monitoring of Drug Tariff prices and drug utilisation (Table 3) , NHS Bury uses existing prescribing decision support systems to provide price change information in their recommendations to GPs about which preparations to prescribe • However, the manufacturers of some branded generics seek to undercut Drug Tariff prices • Occasionally, these manufacturers are 'caught short' if the Tariff drops below current prices of branded generics • As a result, the manufacturers of these branded generics typically reduce their prices to maintain their promise to the PCTs of providing lower cost alternatives to current generics • However, branded generics are not ideal for the NHS as they reduce the discounts and rebates potentially available to community pharmacies. This shortfall has to be made up out of their other payments, which is not ideal • Branded generics also reduce competition amongst generics suppliers. Consequently, branded generics are typically not recommended by PCTs in their prescribing support systems B) Outcomes • It is diffi cult to state the outcome of these monitoring activities among PCTs in England. However, PCTs and community pharmacists need to be alert to the activities of manufacturers supplying branded generics to make sure that neither party loses out in the long term • As a result, provide guidance to other countries and regions in similar circumstances
US-State Medicaid Services [63]
A) Current measures
• State Medicaid programmes have implemented a number of policies in recent years to reduce the rising costs of medications including generics substitution • However, these policies differ in the extent to which pharmacists or patients can infl uence the medications they choose.
States that implemented policies requiring patients' consent prior to generics substitution experienced rates of substitution 25% lower in 2006/2007 than those States that did not B) Outcomes and implications • It was estimated in 2007 that if the States currently requiring patient consent proactively eliminated this, they could save more than US$100 million annually in the coverage of three top-selling medications nearing patent expiration • There would also be savings from existing multiple sourced drugs prescriptions. In addition, reduce the need for pharmacists to spend time addressing possible confusion among patients with associated costs. These issues will be explored further in future issues of this journal.
Potential pitfalls to avoid, based on the experiences of the co-authors, include not fully addressing all key stakeholders when initiating reforms to encourage the prescribing and dispensing of generics as seen in Abu Dhabi, see Table 4 . However, this is now being addressed. In addition, not allowing pharmacists to dispense the cheapest drug once multiple sources are available, which is typically a generic versus an originator drug, in all but a minority of situations that could compromise patient care. Alongside this, delaying the instigation of measures to enhance INN prescribing, compulsory substitution, as well as other measures to enhance the prescribing of particular generics need to be discussed and agreed in advance of their availability, to enhance physician acceptance as seen in Abu Dhabi, Austria and Sweden [7, 14, 17, 49] .
Other pitfalls to avoid include long delays between marketing authorisation and the reimbursement of a generic drug [19] . These issues are also currently being addressed to enable payers to take full fi nancial advantage of the availability of generics. There have also been situations where generics companies have been able to launch new generics ahead of patent loss by launching them in different salts to those of the originator such as generic clopidogrel. This is outside the scope of this paper, but has been explored elsewhere in this issue of the GaBI Journal.
As discussed, we accept there are limitations with the study design. However, we believe the selected case histories provide useful lessons to other countries regarding which measures could potentially further enhance their prescribing effi ciency. The sharing of information about potential policies and measures is vital if Europe is to maintain the ideals of comprehensive and equitable health care. Similarly, in the US, given current fi nancial concerns, there is a greater need than ever before for further measures to help stem the rise in pharmaceutical expenditure.
Conclusion
Payers across countries have successfully introduced multiple supply-and demand-side measures to improve prescribing efficiency through increased use of generics versus originators and patent-protected products in the same or related classes as well as measures to obtain low prices for generics. As a result, they are increasingly able to take full advantage of the availability of generics.
However, this has not always been possible. It is important though that countries continually share their experiences, and even start to accelerate the sharing of lessons learned about which policies and new measures appear the most effective, as resource pressures grow. The alternative is insuffi cient funds to cover the costs of increased drug volumes or new innovative drugs, both of which are not in the best interests of all key stakeholder groups.
For patients
Expenditure on pharmaceuticals is a growing concern among health authorities and health insurance agencies as it is now the largest or equalling the largest component of expenditure in ambulatory, i.e. non-hospital, care. In addition, utilisation and expenditure on pharmaceuticals will continue growing driven by a number of factors including ageing populations, and hence a growing prevalence of chronic diseases leading to greater use of drugs, as well as new drugs being launched that are typically more expensive than existing drugs.
Consequently, health authorities and health insurance agencies welcome the availability of generics as these are priced lower than the originators to help ease resource pressures especially in these diffi cult economic times. However, the extent of the prescribing and dispensing of generics versus originators, as well as similar patent protected drugs in the same class to treat the same patients, varies considerably among countries. This can be due to concerns with the effectiveness of generics versus originators. However, this has been found not to be the case in extensive studies, especially with the tests required by the authorities to demonstrate similar bioavailability between generics and originators before products are launched onto the market. There are also considerable differences in the prices of generics among countries.
Health authorities and health insurance agencies need to tackle both these issue to release considerable resources to help fund comprehensive and equitable health care particularly in Europe without prohibitive increases in either taxes or health insurance premiums. Consequently, they need to learn from each other with respect to measures that have been successful in other countries to enhance the prescribing and dispensing of generics at increasingly lower prices, as well as the pitfalls to avoid. The case histories described in this paper help them to achieve this aim.
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